World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property

NORTHBROOK, Ill., July 7, 2025 /PRNewswire/ -- Hilco Global's real estate sales, commercial industrial and intellectual property practices announce August 15, 2025, as the bid deadline for the bankruptcy sale of a premier contract research organization (CRO) facility formerly occupied by AmplifyBio. Strategically located in West Jefferson, Ohio (Columbus MSA), the sale is being conducted under the direction of the U.S. Bankruptcy Court for the Southern District of Ohio, Case No. 25-52140 | In re: AmplifyBio, LLC.

This sale includes real estate, intellectual property and machinery and equipment, representing a rare opportunity to acquire a fully integrated, purpose-built CRO facility. Built in 2012, the 205,000± SF facility features 65,000± SF of specialized lab space, a 64-room vivarium (34,500± SF) with a one-way traffic flow design and a fully equipped on-site surgical suite—making it ideal for regulated, high-complexity research. The property also features sophisticated infrastructure and enhanced security for sensitive operations.

Engineered to support the development of pharmaceuticals, biotechnology products and medical devices, the facility's integrated laboratories are designed to deliver toxicology, safety pharmacology and bioanalytic characterization capabilities, which are all vital to advancing modern therapeutic innovations.

AmplifyBio, founded in 2021 and supported by over $200 million in funding, quickly established itself as a leader in advanced therapy development. The company specialized in cutting-edge technologies, including gene editing, mRNA and T cell-based therapies and operated state-of-the-art facilities in both Ohio and California. AmplifyBio delivered integrated pre-clinical R&D, safety testing and GMP manufacturing services for a wide range of biopharma clients.

"This sale creates an exceptional opportunity for a buyer to acquire a turnkey operation with Class-A laboratory and office space, tailored for a wide range of advanced research applications," said Joel Schneider, senior vice president at Hilco Real Estate.

Brent Bonham, senior managing director of Hilco Commercial Industrial, added, "This first-class, specialized facility includes an extensive list of highly sophisticated equipment, ideally suited for a broad spectrum of research. It presents a compelling opportunity for CROs and other research companies to acquire well-maintained infrastructure and lab components ready for immediate use."

David Peress, executive vice president with Hilco Streambank, included, "The AmplifyBio patent portfolio represents a unique opportunity to acquire cutting-edge, clinically validated IP at the forefront of immunotherapy and cell engineering. With 119 issued and pending patents spanning non-viral gene editing, antigen-specific TCR identification and engineered T cell therapies, this portfolio includes clinically validated innovations with broad applications across oncology and personalized medicine."

Bids must be received on or before the deadline of August 15, 2025, at 12:00 p.m. (EST) and must be submitted based on the existing stalking horse Asset Purchase Agreement, which can be found for review and download at Hilco Real Estate Sales' website.

Interested bidders should review the court-approved "bid procedures" for requirements to participate in the sale process available on Hilco Real Estate Sales' website. For all inquiries and to request an on-site inspection, please contact Chet Evans at (847) 418-2702 or [email protected].

For additional details, due diligence access and other critical information, visit Hilco Real Estate Sales' Virtual Data Room.

About Hilco Global

Hilco Global, based in Northbrook, Illinois, is the world's leading authority on maximizing the value of business assets by delivering valuation, monetization and advisory solutions to an international marketplace. Hilco Global operates more than twenty specialized business units offering services that include asset valuation and appraisal, retail and industrial inventory acquisition and disposition, real estate, and strategic capital equity investments. US offices are located in Boston, Detroit, Chicago, New York and Philadelphia. International offices include Australia, Canada, UK, Germany, Netherlands, Mexico and locations throughout Asia.

SOURCE Hilco Global